Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29270695 | 0.89 | HDAC6 (0.34) | S1PR1TP53 | |
| SCHEMBL29270832 | 0.87 | S1PR1 (0.32) | S1PR1BDKRB1TP53 | |
| SCHEMBL29270756 | 0.85 | HCRTR1 (0.32) | P2RX3 | |
| SCHEMBL29270721 | 0.85 | CNR2 (0.32) | TP53 | |
| SCHEMBL29270806 | 0.85 | MDM2 (0.32) | P2RX3TP53 | |
| SCHEMBL29270734 | 0.85 | TP53 (0.31) | TP53 | |
| SCHEMBL29270846 | 0.85 | KCNH2 (0.32) | P2RX3S1PR1S1PR4S1PR5 | |
| SCHEMBL26962822 | 0.84 | BDKRB1 (0.36) | P2RX3MAPK14S1PR1BDKRB1 | |
| SCHEMBL29270791 | 0.84 | TRPM8 (0.34) | BDKRB1TP53 | |
| SCHEMBL29270730 | 0.83 | CNR2 (0.32) | MAPK14TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |